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Autoimmune diseases are a family of chronic systemic inflammatory disorders, characterized by the 
dysregulation of the immune system which finally results in the break of tolerance to self-antigen. 
Several studies suggest that Toll-like receptors (TLRs) play an essential role in the pathogenesis of 
autoimmune diseases. TLRs belong to the family of pattern recognition receptors (PRRs) that 
recognize a wide range of pathogen-associated molecular patterns (PAMPs). TLRs are type I 
transmembrane proteins and located on various cellular membranes. Two main groups have been 
classified based on their location；the extracelluar group referred to the ones located on the plasma 
membrane while the intracellular group all located in endosomal compartments responsible for the 
recognition of nucleic acids. They are released by the host cells and trigger various intracellular 
pathways which results in the production of proinflammatory cytokines, chemokines, as well as the 
expression of co-stimulatory molecules to protect against invading microorganisms. Particular, TLR 
pathway-associated proteins, such as IRAK, TRAF, and SOCS are often dysregulated in this group of 
diseases. TLR-associated gene expression profile analysis together with single nucleotide 
polymorphism (SNP) assessment could be important to explain the pathomechanism driving 
autoimmune diseases. In this review, we summarize recent findings on TLR pathways regulation in 
various autoimmune diseases, including Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE), 
multiple sclerosis (MS), rheumatoid arthritis (RA), systemic sclerosis (SSc), and psoriasis.  
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Autoimmune diseases are characterized by the dysregulation of the immune system which finally 
results in the break of tolerance to self-antigen. Even though the accurate etiology and pathogenesis of 
the majority of these diseases are still not clear, complex elements, including genetic, environmental, 
hormonal factors may provoke the autoimmune processes leading to the development of the disease. 
Concerning the role of derailed immune responses in the pathogenesis, aberrant processes both in the 
innate and adaptive immune system have been shown to participate in the disease initiation and 
perpetuation [1]. Within these processes, numerous studies have been demonstrated that Toll-like 
receptors (TLRs) have an essential role in various autoimmune diseases, including Sjögren’s syndrome 
(SS), systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), systemic 
sclerosis (SSc), and psoriasis. [2, 3].  
Toll-like receptors 
The innate immune system is the first line of host defense mechanisms against invading 
microorganisms and forms the basis of the development of adaptive immunity. Host cells express 
diverse pattern recognition receptors (PRRs) include toll-like receptors (TLRs), C-type lectin-like 
receptors (CLRs), Retinoic acid-inducible gene (RIG)-I-like-receptors (RLRs), and Nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs). These can recognize a wide range of 
pathogen-associated molecular patterns (PAMPs). These mechanisms trigger the intracellular signaling 
pathways, which results in releasing of proinflammatory cytokines, chemokines, and interferons (IFNs), 
as well as lead to the expression of co-stimulatory molecules [4].  
TLRs are the most characterized PRRs, which are capable of potently activating different cell types, 
which could be highly expressed on most immune cells, as well as other cell types, including 
chondrocytes, endothelial cells and fibroblasts [5]. Their downstream signaling pathways lead to the 
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production of a wide range of immune-stimulatory cytokines and chemokines [6]. Aberrant activation 
of TLRs may result in unrestricted inflammatory responses therefore the family of TLRs may play a 
pivotal role in the development of autoimmune diseases. 
Ten TLR subtypes have been identified in humans during the last decade. All of them have their 
specific ligands, expression profiles and cellular localization. TLRs belong to the type I transmembrane 
proteins, which are composed of a transmembrane domain, an amino-terminal ectodomain responsible 
for PAMPs recognition, and a cytoplasmic carboxy-terminal toll interleukin-1 receptor (IL-1R) 
homology (TIR) domain [7, 8].  
Among those, TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 are generally regarded as extracellular 
receptors. Since TLR2 addressed as heterodimer in combination with TLR1 or TLR6, while TLR10 
was indicated as originating from the TLR1/TLR6 precursor, they all function as heterodimeric 
receptors and recognize components of microbial cell walls and membranes including peptidoglycans 
and lipopeptides. TLR4 can recognize lipopolysaccharides (LPSs), specific for gram-negative bacteria. 
On the other hand, TLR5 also resides in plasma membranes and engage flagellin, a specific component 
for flagellated bacteria [9–11].  
The family of TLR3, TLR7, TLR8 and TLR9 are intracellular receptors located in endosomal 
compartments and responsible for the recognition of nucleic acids derived from viruses, bacteria and 
the host. Double stranded RNA (dsRNA) activates TLR3, while TLR7 and TLR8 recognize single 
stranded RNA (ssRNA). More specifically, TLR9 recognizes unmethylated CpG DNA [9–11].  
As mentioned before, the TLRs differ in their expression pattern within various cell types. Their signal 
transduction pathways also have different mechanisms [12]. Two main adaptor pathways observed in 
TLRs signaling transduction, namely the myeloid differentiation primary response 88 (MyD88) and 
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TIR-domain-containing adaptor inducing interferon (IFN)-β (TRIF, also known as TICAM1) pathway. 
MyD88 as an adaptor protein could bind directly to the cytosolic domain and lead to induction of gene 
expression via the transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB), activating protein (AP)-1 or interferon-response factor (IRF)-1, 5 and 7. On the other hand, 
TRIF basically transmits the signal downstream and leads to activation of IRF 3 mainly together with 
NF-κB [13–17].  
TLR3 is the only TLR that exclusively uses the TRIF-dependent pathways, whereas the other TLRs are 
restricted to the MyD88-dependent pathway. Exceptionally, TLR4 activates both pathways by first 
leads to activation of the MyD88 pathway at the plasma membrane then activates the TRIF-pathway 
via TRIF-related adaptor molecule (TRAM) at the endosomes [11, 18, 19]. TLR4 was the first 
identified human TLR. TLR4 has been implicated in the recognition of viral structural and 
non-structural proteins, which leads to the production of a wide range of immune-stimulatory cytokines 
and chemokines [6, 20, 21]. Figure 1 summarized the function and signalization of TLRs. Table 1 gave 
the brief summary of the TLR family. 
IL-1 receptor associated kinase (IRAK) family harbors the TIR domain of TLRs. It was originally 
regarded as the serine/threonine kinase associated with the IL-1 receptor [22]. IRAK1, IRAK2, 
IRAK-M, and IRAK4 have been identified so far. Among those, IRAK1 and IRAK4 are two active 
kinases since they could harbor a critical aspartate residue, while this residue is not conserved in the 
other two members of IRAK, so-called inactive ones. IRAK proteins consist of a central kinase domain 
and an N-terminal ligand domain which mediates activation of MyD88. As the result of two kinase 
pathways, NF-κB together with mitogen-activated protein kinase (MAPK) pathways can be activated. 
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Moreover, IRAK1 may play a role in tumor necrosis factor receptor (TNFR) superfamily-induced 
signaling pathways, as well [23].  
MyD88 interacts with a cytoplasmic carboxy-terminal TIR domain of TLRs to recruit IRAK1 and 
IRAK4 upon stimulation. IRAK1 is further phosphorylated by the IRAK4 activation. Activated IRAK1 
subsequently binds to the TRAF domain of TNF-receptor associated factor (TRAF) 6. The 
IRAK1/TRAF6 complex activates another complex which consists of the TGF-β-activated kinase 
1(TAK1) and TAK1-binding proteins including TAB1, TAB2 and TAB3. Phosphorylation of the 
inhibitor of κB kinase (IKK) complex composed of IKK-α, IKK-β and NEMO/IKK-γ and MAPK 
kinase 6 (MKK6) is induced by TAK1, and thereby induces the activation of NF-κB and MAPK [24, 
25].  
Another proinflammatory cytokine, TNF-α, functions as a major mediator of apoptosis as well as 
immunity and inflammation, transduces its signals by binding with TNF receptors (TNFR-I and 
TNFR-II). The role of TNFR-II phosphorylation on its signaling properties is less understood than that 
of TNFR-I. TNFR-I takes most responsibility of TNF-α signaling when the death domain interacts with 
the death domain-containing adaptor proteins such as TNFR associated death domain (TRADD). Upon 
TRADD binding to the TNFR-I, it may lead to the recruitment of receptor interacting protein (RIP) and 
TRAF2 in separate manner for NF-κB activation for the cell-protective pathway. While the recruitment 
of the complex of TRADD and Fas-associated death domain (FADD) results in programmed cell death 
[26]. On the other hand, TNFR-II does not contain this death domain in the cytoplasmic tail. The 
intracellular domain of TNFR-II contains a consensus motif that allows binding to TRAF2 directly 
[27–29].  
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The TRAF proteins are composed of 4 domains, which include the multiple zinc finger repeats (TRAF 
Zn-finger) that are involved in effector functions (essential for the activation of downstream signaling 
cascades), an amino-terminal really interesting new gene (RING)-finger, the N-terminal (TRAF-N) 
coiled-coil domains and the C-terminal (TRAF-C) domains [30].  
In comparison with other TRAFs, TRAF6 has the most divergent TRAF-C domain and shows the least 
homology to the prototypical TRAF domain sequence [31]. There are distinct differences in peptide 
binding to TRAF6 and to the other TRAFs due to the special structure of TRAF6. Therefore, TRAF6 
has its unique biological function. TRAF6 is a convergence point for both upstream and downstream 
signaling cascades. It regulates a variety of physiologic processes, including both innate and adaptive 
immunity, bone metabolism, cell proliferation together with differentiation and many others [32]. 
Unlike other TRAFs, which only mediate signaling from the TNFR superfamily, TRAF6 also 
participates in the signal transduction of IL-1R/TLRs to activate inflammatory and apoptotic signaling 
pathways [33, 34]. 
Suppressor of cytokine signaling (SOCS) 1 was first identified and reported by three research groups 
with different methods in 1997. From then on, SOCS family set an important insight into the 
unelucidated mechanism of cytokine signaling. SOCS 1 is also known as JAK-binding protein (JAB) or 
STAT-induced STAT inhibitor (SSI) 1 [35–37]. The SOCS family contains eight protein members, 
which are cytokine-inducible Src homology 2 (SH2) protein (CIS), SOCS1, SOCS2, SOCS3, SOCS4, 
SOCS5, SOCS6 and SOCS7. They all have a central SH2 domain, an amino-terminal domain of 
variable length and sequence, and the SOCS box which has a segment with a carboxy-terminal 40 
amino acids. Activation of the intracellular molecules, including Janus family kinases (JAKs) and 
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signal transducers and activators of transcription (STATs), is essential for the cytokine signaling 
[35–37].  
The SOCS family of proteins is regarded as key participants of the negative feedback loop that 
regulates the intensity, duration and quality of immune cytokine signaling. Among the others, SOCS1 
is one of the best characterized family members which is one of the multiple targets of miR-155. We 
have previously shown the expression pattern of miR-155 as well as the gene expression of SOCS1 in 
SS patients. (unpublished data) 
Cytokines such as IFN-γ, TNF-α, together with IL-4 up-regulate the gene expression of CIS, SOCS1, 
SOCS2 and SOCS3 mRNA. SOCS1 is also functioning as an inhibitor of the LPS-activated TLR 
signaling pathway through directly blocking IRAK1 and IRAK-4 [7, 38]. MyD88-adaptor like (Mal) is 
regarded as bridge for interacting with MyD88 of TLR2 and TLR4 signaling. SH2 domain of SOCS1 
could recognize phosphorylated Mal and induce polyubiquitination and subsequent proteasomal 
degradation [39].  
Targeted proteins and pathways of Toll-like receptors are summarized in Figure 2. 
Table 2 summarized the structure of IRAK, TRAF and SOCS family protein. 
Primary Sjögren’s syndrome  
Sjögren’s syndrome (SS) is a slowly progressive systemic autoimmune inflammatory disease that 
primarily affects middle-aged women (female to male ratio: 9:1), although it may be found in all ages 
including childhood. The target organs are salivary and lachrymal glands. Therefore, patients show 
symptoms of dry mouth and dry eyes [40]. Beside the pathognomonic glandular symptoms (GS), other 
systemic symptoms, denoted as extraglandular manifestations (EGMs), also found in approximately 
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one third of the patients. These patients frequently complain about fatigue, Raynaud’s phenomenon, 
muscle and joint pain [41].  
The expression profile of various TLRs is quite different in primary SS patients compared to that of 
healthy individuals [42]. Cultured salivary gland epithelial cells (SGECs) have been shown to express 
functional TLR2, TLR3 and TLR4 following treatment with their respective ligands. The TLR1, TLR2 
and TLR4 mRNAs are significantly over-expressed in primary SS SGECs compared to controls [42, 
43]. The expression level of TLR2, TLR3 TLR4 and MyD88 is higher in the labial salivary glands of 
SS patients compared to controls. Therefore it is informative to assess them in different salivary gland 
cell types, including acinar cells, infiltrating mononuclear cells and ductal epithelial cells. The TLR 
expression level showed similar pattern in all types of human salivary gland cells [44]. As mentioned 
before, peptidoglycans could activate TLR2, which has been indicated to induce the production of 
interleukins such as IL-17 and IL-23 in the peripheral blood mononuclear cells (PBMCs) of SS patients 
via IL-6, signal transducer and activator of transcription (STAT) 3 and NF-κB pathways [45]. 
We reported previously the concurrent over-expression of miRNA-146 and TRAF6 gene in primary SS 
patients compared to controls [46]. The over-expression of TRAF6 is surprising since miR-146a could 
inhibit the expression of TRAF6 [47]. In the same patient pool, we could demonstrate a similar pattern 
with the concurrent enhanced expression of miRNA-155 and SOCS1. In both cases the over-expression 
of TRAF6 and SOCS1 was related to the levels of miRNA-s. These phenomena may be explained by 
the following possible reasons: a.) existence of chronic persisting EBV infections; b.) the function of 
TRAF6 and SOCS1 might be complemented by other TRAF and SOCS molecules and signaling 
factors; c.) miR-146a and miR-146b are not the only miRNAs which targets TRAF6 protein whereas 
miR-155 is also not the only miRNA which targets SOCS1 protein.  
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Previously we have assessed circulating cytokines in primary SS patients compared to healthy controls 
and found amongst others that serum interleukin-10 level was significantly decreased in primary SS 
patients [48]. The impaired IL-10 signaling might be associated with SOCS1 induction. 
Overexpression of SOCS1 in primary SS could be correlated to these results. 
 
Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is the most prevalent systemic autoimmune disease which has a 
large spectrum of clinical presentations since SLE can affect multiple organs, including skin, joints, 
kidneys, lungs, nervous system, and serous membranes. Its diversity of clinical features is matched by 
the complexity of the pathogenetic factors including genetic, hormonal, and environmental factors [49]. 
Human plasmacytoid dendritic cells (pDCs) regarded as critical elements involved in the pathogenesis 
of autoimmune diseases [50]. They can produce cytokines and chemokines in response to 
autoimmune complexes including self DNA and small nuclear ribonucleoprotein particles (snRNPs) in 
SLE through a cooperative interaction between TLRs and Fc-γ receptors (Fc-γ-Rs) [51, 52]. Both 
TLR7 and TLR9 are associated with the stimulation of B cells and the production of IFN-α in SLE. 
TLR7 shown higher expression level on human pDCs compared with the other RNA-activated 
endosomal TLRs, TLR3 or TLR8 [51]. TLR7 binding with U1 snRNP mediated by Fc-γ-Rs results in a 
massive release of IFN-α [51]. TLR7 antagonists could inhibit IFN-α production by pDCs in response 
to nucleic acid-containing immune complexes [52, 53]. On the other hand, it is also believed that the 
production of type I IFN (i.e. IFN-α and IFN-β) and TNF-α in SLE is highly related with TLR9 [53]. 
The immune complexes derived from serum of SLE patient are translocated to the endosome for 
activating TLR7 or TLR9, resulting in dimerization and internalization leads to IFN-α or TNF-α 
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secretion. Increased levels of IFN-α in serum and higher expression level of IFN-inducible genes in 
PBMCs extracted from SLE patients have been suggested to be responsible for severe stage of disease 
activity [54, 55]. Activation of TLR9 through transcription factor IRF7 which is activated by the 
adaptor MyD88 leads to high level of IFN induction. The MyD88/IRF7 complex together with 
A/D-type CpG oligodeoxynucleotide (CpG-A, an IFN-inducing TLR9 ligand) are normally retained in 
the endosome of pDCs. CpG-A is rapidly transferred to lysosome when in conventional dendritic cells 
induces the production of type I IFN [56]. During immune stimulation uridine-rich RNAs are 
recognized by pDCs via TLR7, while human monocytes and myeloid DCs through TLR8 [51]. 
Myeloid DCs respond to TLR7/8 ligands via Fc-γ-Rs, which leads to the production of IL-12 and the 
induction of T helper type 1 (Th1) cell proliferation [57]. 
Interferon, TNFs and specific interleukins are induced by TLRs. For instance, the expression of TNF-α, 
IL-6 and IL-23, IL-10 is induced by TLR4 activation [58]. TLRs are activated in response to 
accumulation of apoptotic bodies. TLRs 7 and 9 expression levels were significantly increased in 
African American and European American lupus patients compared to age-matched controls. Serum 
levels showed significant increase in expression of IL-6, INF-α, IFN-γ and TNF-α in lupus patients 
compared to healthy individuals [59]. 
The TLR4 polymorphism has not been found to be associated with the susceptibility to SLE so far. The 
Mal protein, also known as the TIR domain-containing adaptor protein (TIRAP), is implied to have a 
role in modulating intracellular signaling triggered by the MyD88-dependent TLR2 and TLR4. The 
Leu180 allele of MAL/TIRAP polymorphism indicated reduced susceptibility to SLE regarded as a 
protective factor against the development of SLE [60] .  
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The single nucleotide polymorphisms (SNPs) of TLR7 rs3853839, TLR8 rs3764880, together with 
TLR9 rs351240 have been shown to increase the risk of SLE in an Asian population [61, 62]. 
Moreover, the SNPs of TLR9 rs352139 and rs351240 are associated with lupus nephritis [63]. In a 
Danish population, the SNPs of TLR3 rs3775291, TLR8 rs3764879, TLR9 rs352143 all showed 
association with SLE. The mRNA expression levels of TLR7 and TLR8 also significantly higher in 
SLE patients than in healthy controls [64]. These results indicate that genetic variations of certain TLR 
gene expression are implicated in the pathogenesis of the disease, which together associate 
with SLE susceptibility and clinical phenotype development.  
The polymorphisms (rs11465955, rs1624395, rs1152888 and rs1370128) of IRAK-M in 
2033 SLE patients compared with 2357 healthy controls from four independent European-descent 
populations (Spain, Germany, Italy and Argentina) were checked previously. The SNP rs1152888 of 
IRAK-M was not associated with SLE in this populations, while the other three showed differences 
between patients and controls [65]. 
However, the expression and pathophysiological role of TNF adapters in SLE have been poorly 
understood so far. Zhu L et al. found that the expression of mRNA for TNF adapter molecules TRADD 
protein, FADD protein, RIP, and TRAF2 decreased significantly in PBMCs from patients with SLE. 
Moreover the expression of these adapters were negatively correlated with the SLE disease activity 
index (SLEDAI). These abnormalities may be involved in the immunopathogenic injury mediated by 
the aberration TNF-α signaling pathway in SLE [66].  
Being expressed in immune cells, suppressors of cytokine signaling proteins, CIS, SOCS1, SOCS2 and 
SOCS3, can regulate cytokine signaling and immune responses. To evaluate the possible expressional 
dysregulation of CIS, SOCS1, SOCS2 and SOCS3 in SLE and RA patients, the transcript levels of 
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these genes in PBMCs from SLE and RA patients were determined and statistically compared with 
those in PBMCs from healthy individuals. SLE patients with active disease significantly express higher 
CIS transcript levels than normal individuals and SLE patients with inactive disease, whereas the 
difference in SOCS1, SOCS2 and SOCS3 transcript levels between normal individuals 
and SLE patients are not statistically significant. These data suggest that CIS can serve as 
an SLE disease marker and may be involved in the pathogenesis of SLE, and that TNF-α may play an 
important role in the regulation of CIS and SOCS2 gene expression in PBMCs in vivo [67]. In 
monocytes higher expression level of STAT1 proteins was shown from SLE patients compared to 
controls, which also positively correlated with SLEDAI. The expressions of phospho-STAT1 protein 
and SOCS1 gene in the skin lesion from patients with SLE were both up-regulated compared with 
normal skin tissue from healthy controls. In conclusion, the JAK-STAT1 signaling pathway was 
hyperactivated while SOCS1 was down-regulation in skin lesions and monocytes of Asian SLE 
patients [68].  
Additionally, TLR2 and TLR4 could be necessary for the initiation of antiphospholipid antibodies 
production and activation of the endothelium, resulting in thrombosis development in the pathogenesis 
of antiphospholipid syndrome secondary to SLE [69].  
 
Multiple sclerosis 
Multiple sclerosis (MS) is an autoimmune neurological disease which affects the brain and the spinal 
cord leads to a main triad symptoms of inflammation, demyelination and gliosis. MS is causing the 
nerve signals to slow down or even stop due to damaged or lack of the protective covering of myelin 
sheath surrounding the nerve cells, resulting in single or multiple symptoms including motor 
 14 
disabilities, speech disabilities, swallowing disabilities, visual disabilities and other neuronal problems. 
[70] 
The activation of the transcription factor NF-κB may be implied in the microglial response to myelin 
damage in MS lesions. Up-regulation of NF-κB controled adhesion molecules and cytokines result in 
enhancement of the inflammatory reaction [71]. After stimulation with TLR ligands and cytokines that 
induce NF-κB, the expression of NF-κB DNA-binding activity was elevated in macrophages of MS 
patients [72].  
TLR ligands have also been identified as T-cell promoter of MS [73]. TLRs have diverse roles in 
forming of axonal path, dorso-ventral patterning together with cell-fate determination. Specifically, 
TLR2 and TLR4 differentially modulate adult hippocampal neurogenesis through unknown ligands 
[74]. TLR ligands can inhibit the differentiation of several cell types; TLR2 ligands can suppress the 
process that the mesenchymal stem cells differentiated into osteogenic, adipogenic, and chondrogenic 
cells [75]. The expression of TLR2 observed on oligodendrocytes, while higher expression of TLR2 in 
MS lesions. Hyaluronan receptor is capable of inhibiting the maturation and remyelination 
oligodendrocyte precursor cells (OPCs) via TLR2 [76]. TLR2 also associated with the high levels of 
hyaluronan found in the areas of complete demyelination in MS. Altered TLR2 activation results in the 
dysfunction of hyaluronan synthesis and degradation on oligodendrocytes, which may imply the 
adequate remyelination blockade [77]. TLR9 was identified in B cells and pDCs [78]. Human TLR9 is 
only found on pDCs and is able to recognize viral DNA within the early endosomes at the initial phase 
of viral infections since TLR9 recognizes unmethylated CpGDNA [79]. Both TLR2 and TLR9 has 
been associated with the response to several human viral infections, including cytomegalovirus, 
hepatitis C, EBV, varicella zoster virus and herpes simplex viruses types 1 and 2 (HSV)  [80–82]. 
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Activation of TLR2 induces the production of proinflammatory cytokines, including IL-6, IL- 8, and 
TNF-α. Moreover, TLR9 stimulated by HSV triggers the production of IFN-𝛼 [83]. Furthermore, 
TLR7 also play a role implied in MS. TLR7 trigger the maturation and differentiation status of B cells 
into immunoglobulin (Ig)-secreting plasma cells leads to the releasing of IgM and IgG. It is indicated 
that deficient TLR7-induced Immunoglobulin production in MS recently. The MS aggravation could be 
associated with impaired immune responses against infections with TLR7-recognized RNA viruses [84, 
85].  
The SNP rs243324 of SOCS1 variant regarded as risk factor for MS in a separate cohort of 3919 MS 
patients and 4003 controls in Spain population. Moreover, its T allele was increased in relapsing 
remitting (RR) MS which also named secondary-progressive MS patients than primary-progressive MS 
patients [86].  
SOCS proteins, especially SOCS1 and SOCS3, not only expressed in immune cells but also have been 
described in the cells of the central nervous system (CNS). Besides the immunomodulating functions in 
the immune system, SOCS family also activate microglia, macrophages and astrocytes [87]. A 
moderated negative correlation has been depicted between SOCS1 and SOCS3. SOCS1 transcription 
level was lower in the peripheral blood leukocytes of MS patients compared with healthy controls, 
while SOCS3 was shown to have higher transcription level [88]. The presence of SOCS1 inhibit the 
process of IFN-γ induction of TNF-α secretion and STAT-1α and NF-κB activation, results in the 
reduction of CD40 both at protein and mRNA levels [89].  




 T cells from RR MS patients during relapse 
compared with MS patients in remission [90]. Lower expression level of SOCS3 results in increasing 
the activation of STAT3, causing massive release of the hormone leptin in CSF of MS patients and 
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other MS lesions [91]. Leptin has the function of triggering TNF-α, IL-6 and IL-10 expression in 
monocytes of relapsing MS patients but not in monocytes of the patients with stable disease stage. 
Indeed, decreased SOCS3 expression level during relapses might account for overexpression of 
leptin-mediated cytokine in MS [92].  On the other hand, Th17 cells have been implied to have an 
essential role in pathomechanism of autoimmune diseases. Th17 cell lineage transcription factors, 
signal transducer and activator of the transcription (i.e. STAT 3) lead to the activation of the specific 
cytokines close associated with Th17, including IL-17A, IL-17F, IL-21 and IL-22. It is indicated that 
IL-1 receptor type 1 (IL-1R1) signaling is highly related with the differentiation and activation of Th17 
cells. IL-1R1 signaling induces Th17 cell differentiation results in the expression of IRAK4 together 
with retinoic acid-related orphan nuclear hormone receptor (ROR). Therapeutic strategies with 
inhibiting IL-1R1 signaling can be regarded as a novel approach for the treatment of MS based on the 
role of IL-1 signaling and Th17 cells in the development of the autoimmune processes and autoimmune 
diseases. Negative regulators including inhibitory membrane-bound IL-RII, the regulatory IL-1R1 
antagonist (IL-1R1a) and the IL-1R1-signlaing-induced single Ig IL-1R-related (SIGIRR) suppress 
excessive IL-1 signaling and Th17 cell differentiation [93]. IFN-β has been used as preferred therapy 
for MS by suppressing the differentiation of Th17 cells via inducing the production of 
Th17-suppressive cytokines including IL-27 and IL-12 in DCs. SOCS3 regarded as important regulator 
of leptin-mediated protein, inhibited the production of the Th17-promoting cytokines IL-6 and IL-23 
[94]. Surprisingly, statins used for controlling cholesterol levels such as simvastatin also have 
anti-inflammatory and immunomodulatory effects. It induces SOCS3 expression in monocytes from 
RR MS patients leads to the lower activation of STAT1 and STAT3, which blocks the development of 
Th17 cells. The production of Th17-promoting cytokines IL-6 and IL-23 is further inhibited as the 
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result, leading to the decreased IL-17 production and inhibition of the expression of IL-17 transcription 
factor RORC in CD4
+
 T cells [95, 96]. Statins blocks the development of Th17 might be protective in 
MS, therefore, they are being tested in clinical trials in MS patients currently [97]. 
Additionally, torque teno virus (TTV) also involed in the pathogenesis of MS. TTV interact with TLRs, 
which leads to the production of inflammatory cytokines, contributing to the chronic disease 
progression in MS patients. Overexpression of TLR9 on monocytes of MS patients is correlated with 
higher titers of TTV in blood [98].  
 
Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a common autoimmune disorder with prevalence rates approximately 1% 
of the adults worldwide. The disease primarily affects the synovial joints and the chronic inflammatory 
process consequently causes the destruction of the articular tissue [99].  
Several genetic studies address the association of the common SNP of TLR and the pathogenesis of RA. The 
results somewhat vary from region to region. The TLR9 SNP rs187084 allele variant TT may increase RA 
susceptibility in the Turkish RA population, although it was not associated in studies of Dutch or French 
cohorts [100–102]. Furthermore, the SNP rs5741883 of TLR8 has been reavealed to have association with 
rheumatoid factor autoantibody positivity in a cohort study on 319 European individuals [103].  
Besides the assessment of SNP of TLRs in RA patients, functional studies on TLRs in human RA samples 
identified increased activation status of these receptors. It is suggested that the adaptor protein used by most 
TLRs, MyD88, is essential in matrix metalloproteinase (MMP) production which is responsible for the tissue 
destruction and remodeling in RA synovial membrane cultures [104]. Therefore, TLRs have potential 
involvement in the inflammatory and destructive processes in RA. Furthermore, TLR3 can also promote 
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osteoclasto-genesis via up-regulation of receptor activator of nuclear factor κB ligand (RANKL, also known 
as osteoclast differentiation factor) on RA synovial fluids (SFs) causing chronic inflammation [105]. RA 
necrotic synovial fluid cells have been shown to release RNA regard as endogenous TLR3 ligand that can 
activate TLR3 on RASFs [106]. 
TLR signaling pathways have correlated with the development and maintenance of RA. Many studies 
have investigated the expression and function of TLRs in synovial tissue cells from patients compared 
with tissue samples from osteoarthritis (OA) patients or healthy controls. All endosomal TLRs included 
TLR3, TLR7, TLR8 and TLR9 expressed not only in peripheral blood but also in human synovial 
tissue of RA patients [106–108]. A variety of TLRs including TLR2, TLR3, TLR5, TLR6, TLR7 and 
TLR9 shown overexpression in the synovium of RA patients compared with healthy controls or OA 
patients [109–111]. TLR2 has essential pathogenic function in RA, activation of synovial fibroblasts 
via TLR2 induces the production of multiple inflammatory chemokines including IL-1β and TNF-α in 
RA joints [112, 113]. TLR2 and TLR4 expression was found associated with the presence of IL-12 and 
IL-18 in RA synovial tissue [111]. Activation of TLR-3 and TLR-7/8 resulted in a skewed balance 
toward IL-12 [114]. DCs derived from RA patients have shown elevated levels of inflammatory 
cytokines such as TNF-α and IL-6 mediated by activation of TLR2 and TLR4 compared with healthy 
controls [114]. Stimulation of synovial fibroblasts with the TLR3 ligand results in releasing IL-6, 
MMP-3 and MMP-13 [108]. It is observed that TLR8 induced the massive secretion of TNF from RA 
synovium. By using imiquimod (inhibition of spontaneous TNF production) specifically inhibit TLR8 
[107]. 
Further data on the contribution of these TLRs in the perpetuation of inflammation in RA comes from  
studies with antimalarial drugs, such as chloroquine, hydroxychloroquine, and quinacrine, which have been 
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used to treat RA in the last century [115, 116]. These drugs act as antagonists of TLR9 and inhibit 
endosomal acidification [117]. They could also interact directly with nucleic acids, causing modifications 
which prevent their binding to the endosomal TLRs [118]. 
SOCS protein levels can dramatically modulate cellular responses to cytokines through the JAK-STAT 
pathway. The overexpression of SOCS1 and SOCS3 were detected in PBMCs from RA patients 
compared with healthy controls could relate with the up-regulation of SOCS1 in T cells and SOCS3 in 
monocytes. SOCS1 also had higher expression in the synovial membranes from RA patients compared 
with OA patients. Moreover, SOCS2 was up-regulated in T cells. Intriguingly, T cells in synovial fluid 
expressed lower levels of SOCS molecules than in the peripheral blood. Furthermore, macrophages in 
synovial fluid have higher levels of SOCS molecules than in the peripheral blood. [119] The transcript 
levels of CIS, SOCS1, SOCS2 and SOCS3 genes in RA patients compared with normal individuals 
were not reaching statistical significant level. However, the RA patients group using treatment with  
TNF-α blocking agent appeared to have over-expression level of CIS, but lower-expression of SOCS2 
in PBMCs [67]. 
The expression of TNF-α and related signaling molecules were detected in PBMCs from 27 Indian RA 
samples and 30 controls. Significant overexpression of TNF-α and TNFR-I together with increased 
expression of TRADD, RIP, and TRAF2 mRNA indicated the enhanced signaling through 
TNFR-I-TRADD-RIP-TRAF2 pathway in RA patients compared with controls. Lower expression of 
FADD may suggest the suppressed signaling via TNFR-I-TRADD-FADD pathway [120]. 
Even though the role of variations in the TNF-α gene remains not completely known for the 
pathomechanism of RA, the factors regulating TNF-α signaling may contribute to RA susceptibility.  
The TRAF family members are one of the most characterised molecules transducing cytokine signals 
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from their cell surface receptors and activating downstream intracellular signaling cascades. The SNP 
rs7514863 of the TRAF5 gene identified a significant association across the entire cohort of 1273 cases 
with RA compared with 2463 healthy controls of UK Caucasian population [121].  
Lee A et al. studied the TNF-α driven inflammatory program in fibroblast-like synoviocytes (FLSs) 
obtained from the synovial tissues of patients with RA. They discovered the TNF-α induced prolonged 
activation of NF-κB signaling and sustained transcriptional activity in FLSs of RA compared with OA. 
Moreover, lower expression of the feedback inhibitors A20-binding inhibitor of NF-κB activation 3 
(ABIN3), IRAK-M, SOCS3 and activating transcription factor 3 (ATF3) was indicated in FLSs. Since 
those four factors may terminate inflammatory responses in macrophages, while in FLSs they had 
lower expression, resulting in uncontrolled inflammatory response which leads to persistent synovial 
inflammation in RA [122].  
 
Systemic sclerosis 
Systemic sclerosis (SSc) characterized by sclerosis in multiple systems including skin, lungs, the 
gastrointestinal tract, kidneys and the musculoskeletal system. SSc is classified into two sub-groups 
based on the extent of skin thickening: limited SSc and diffuse SSc. The limited form is at lower risk of 
visceral involvement, while the diffuse form involves several systems of internal organs. [123] 
It is believed that many TLRs participate in the development of the dysfunction of the immune system 
in SSc. For instance, TLR agonist S100A8/A9 regarded as a novel possible marker for SSc phenotype 
[124]. A SNP of TLR2 (Pro631His) variant was suggested to be associated with the diffuse form of 
SSc and the development of pulmonary arterial hypertension (PAH) [125].  
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On the other hand, Siglec-1(CD169, sialoadhesin) is a IFN-regulated gene that was regarded as 
macrophage marker. Certain TLR agonists, including TLR-7 and TLR-9, trigger the induction of 
Siglec-1 mRNA and surface protein expression in circulating monocytes and tissue macrophages of 
SSc patients compared with healthy controls. By immunohistochemistry, they observed higher amounts 
of Siglec-1+ cells in the skin of SSc patients compared with controls. Up-regulated certain TLRs 
through the IFN-mediated gene imply their essential role in the pathomechanism of SSc [126]. 
The T-cell attracting and profibrotic chemokine CCL18 shown higher levels in SSc. The 
monocyte-derived DCs matured with the TLR4 ligand LPS from SSc patients release significantly 
increased levels of IL-10 compared with healthy controls, which suggest a role for TLR4 ligands in the 
pathogenesis of SSc [127]. 
Other profibrotic and proangiogenic chemokines such as CCL2 and CXCL8 have also shown relation 
with SSc. CCL2 production was sensitive to both inhibition of proteasome and JNK, while CXCL8 
production was sensitive only to inhibition of proteasome. Excessive production of these two 
chemokines in antifibroblast antibodies (AFAs)-stimulated fibroblast culture supernatants resulted in 
activation of ERK-1/2, c-Jun, and NF-κB. Furthermore, anti-human TLR4 monoclonal antibodies 
(mAb) partially inhibited the production of CCL2 induced by AFAs in human fibroblasts, in other 
words, CCL2 induction is TLR4 dependent [128].  
Autoantibodies that bind to the surface of fibroblasts may contribute to the pathogenesis of SSc. 
Furthermore, EBV activates TLR pathway in infected SSc fibroblasts. In EBV/p2089-infected SSc 
fibroblasts (in vitro), a significant induction of mRNA expression levels of TLR7 and TLR9, selected 
IFN-stimulated genes (ISGs), IRF7, IRF5, and IRF4 have been described [129]. 
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MMPs are capable of degrading all extracellular matrix (ECM) components [130]. Tissue inhibitors of 
metalloproteinase (TIMPs) are induced by MyD88-dependent TLRs, especially TLR8, selectively 
inhibits MMPs to block the breakdown of ECM [130, 131]. TIMP-1 is the most characterized enzyme 
among the TIMP family since it can inhibit most MMPs [130]. Therefore higher serum concentrations 
of TIMP-1 result in the increment in the ratio of TIMP/MMP of patients with SSc [132–135]. Increased 
TIMP-1 production has been described in circulating monocytes of SSc compared with RA patients 
and controls. When SSc and control monocytes were stimulated with TLR8 agonist, TIMP-1 
production dramatically elevated, underlining the role of TLR signaling in ECM remodeling [136].  
 
Psoriasis 
Psoriasis is a chronic and frequently relapsing inflammatory skin disease characterized by 
pathologic features such as accelerated epidermopoiesis, marked hyperkeratosis with parakeratosis 
(abnormal maturation), vascular dilatation, and inflammatory cell infiltration. The most common 
form of the disorder is the chronic plaque psoriasis with rounded erythematous, dry, scaling 
patches. The lesions have a predilection site as nails, scalp, genitalia, extensor surfaces, and the 
lumbosacral region. The etiology of the disease is not fully understood, but genetical factors are 
highly believed to be involved [137]. 
TLR1, TLR2, and TLR5 have been detected constitutively expressed on the normal keratinocytes in the 
epidermis. Interestingly, the expression of TLR1 and TLR2 on keratinocytes in the psoriasis skin 
lesions is further upregulated [138]. The higher expression of TLR4 in guttate psoriasis was indicated 
compared with plaque psoriasis and normal controls [139]. The enhanced TLR2 expression could 
further upregulate TLR4 expression in epidermal and dermal DCs of psoriatic skin [140]. Psoriatic 
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keratinocytes induce high levels of inflammatory mediators and become hyperproliferative upon IFN-γ 
and TNF-α stimuli, resulting in thickening of the skin. The TLR-7/8 agonist imiquimod stimulated 
IFN-γ and enhanced DCs infiltration, resulted in psoriatic exacerbations [141]. Among the other TLRs, 
TLR5 and TLR9 were upregulated by transforming growth factor-α (TGF-α) in psoriatic epidermal 
keratinocytes [142].  
The common coding variants of TRAF3IP2 gene p.Asp10Asn allele (rs33980500) regarded as risk 
factor for psoriatic arthritis. Down-regulated TRAF3IP2 variant disrupted the binding property to 
TRAF6, indicating altered modulation of immunoregulatory signaling such as IL-17 in a German 
population [143, 144]. 
IFN-α and skin infiltrating activated T lymphocytes are also involved in the pathogenesis of psoriasis. 
Down-regulation of the SOCS3 together with SH2-domain-containing protein-tyrosine phosphatase 
1(SHP1) in response to IFN-α was found in the psoriatic T cells compared to that of healthy controls 
[145]. Intriguingly, SOCS1, SOCS2, and SOCS3 proteins were barely undetectable and only weakly 
expressed in atopic dermatitis skin [146]. MiR-203 is the keratinocyte-derived microRNA with a 
highly skin-specific expression profile. Its up-regulation in psoriatic plaques was concurrent with 
down-regulation of SOCS3, which is a miR-203 conserved target [147].  
Conversely, Federici M et al. found exaggerated expression of SOCS1 and SOCS3 in the psoriatic 
epidermis and allergic contact dermatitis in the IFN-γ and TNFα-activated psoriatic keratinocytes. By 
sustaining the activation of the PI3K/AKT pathway in keratinocytes, SOCS1 and SOCS3 could 
suppress cytokine-induced apoptosis by blocking the proteasome [148]. SOCS1 mimetic peptide to 
control IFN-γ-mediated skin disorders is regarded as a new future perspective in psoriasis therapy 
[149].  
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The expression of TNF-α and IL-8 induced by the TLR2, TLR3 and TLR4 signaling pathways via 
NF-κB nuclear translocation in human psoriatic keratinocytes have been described previously [150]. 
Some immunosuppressive therapies, such as pimecrolimus and tacrolimus work in the way that 
suppress TLR2 signaling, which leads to down-regulated of TNF-α and IL-8 mRNA expression in 
human keratinocytes to control psoriatic inflammation [151]. Topical retinoids also works as TLR2 
inhibitors [152]. While monomethylfumarate interferes with LPS signaling that inhibits NF-κB via 
TLR 4 in dendritic cells results in lower expression of IL-12p70 and IL-10 [153].  
Tables 3 summarized the association between SNPs and autoimmune diseases, while Table 4 
summarized the association between TLRs and autoimmune diseases. 
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Future prospects 
Activation of TLRs plays an important role in cytokine production in autoimmune diseases. IRAK, 
TRAF and SOCS proteins are regarded as the main modulators of the TLR pathways. Addressing their 
gene expression profile together with SNP elucidation could be important to explain this aspect of the 
pathomechanism driving autoimmune diseases. Moreover, more targeted therapeutical potential could 
be utilized with more background knowledge on the TLRs family, such as statins use for the treatment 
in MS. Further studies on the identification of new families of other innate receptors (CLRs, NLRs and 
RLRs) and their signaling pathways will help to understand individual TLR responses in innate 
immunity and aid more precisely in pinpointing therapeutic targets in patients with autoimmune 
diseases. 
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Legends to figure 
Fig. 1 Function and signalization of Toll-like receptors 
Ten Toll-like receptors (TLRs) are grouped into extracellular (TLR1, TLR2, TLR4, TLR5, TLR6 and 
TLR10) and intracellular (TLR3, TLR7, TLR8 and TLR9) subtypes. TLR10 was indicated as 
originating from the TLR1/TLR6 precursor. TLR2 addressed as heterodimer in combination with 
TLR1 or TLR6. Different components of microbial cells could activate extracellular subtype TLRs, 
while TLR3, TLR7/TLR8 and TLR9 recognize viral double stranded RNA (dsRNA), single stranded 
RNA (ssRNA) and unmethylated CpG DNA, respectively.  
Myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing adaptor inducing 
interferon (IFN)-β (TRIF) are two main adaptor pathways in TLRs signaling transduction. These two 
adaptor pathways transmit the signal downstream and lead to induction of gene expression via 
transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), 
activating protein (AP)-1 or interferon-response factor (IRF) 1, 3, 5 and 7. TLR3 is the only TLR that 
exclusively uses the TRIF-dependent pathways, whereas the other TLRs are restricted to the 
MyD88-dependent pathway. Exceptionally, TLR4 triggers both pathways by first activating the 
MyD88 pathway at the plasma membrane then the TRIF-pathway via TRIF-related adaptor molecule 
(TRAM) at the endosomes. 
 
Fig. 2 Targeted proteins and pathways of Toll-like receptors 
TLRs interact with Myeloid differentiation primary response 88 (MyD88) through MyD88-adaptor like 
(Mal). Activated IL-1 receptor associated kinase (IRAK) 4 could further phosphorylated IRAK1. 
Activated IRAK1 binds to TNF receptor associated factor (TRAF) 6 to form the IRAK1/TRAF6 
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complex, which activates TGF-β-activated kinase 1(TAK1) and their binding proteins (TAB1, TAB2 
and TAB3) complex. Subsequently activates inhibitor of κB kinase (IKK) complex (IKK-α, IKK-β and 
NEMO/IKK-γ) and mitogen-activated protein kinase (MAPK) in different pathway, leads to activating 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activating protein (AP)-1. 
Furthermore, IRAK1 also imply a role in tumor necrosis factor receptor (TNFR) superfamily-induced 
signaling pathways. The TNFR separates into two groups based on whether the death domain presence 
or not. When TNFR-I interacts with the TNFR associated death domain (TRADD), it may lead to the 
recruitment of receptor interacting protein (RIP) and TRAF2 for NF-κB activation. The recruitment 
with Fas-associated death domain (FADD) result in programmed apoptosis. Even though the TNFR-II 
does not contain the death domain, the intracellular consensus motif could bind to TRAF2 directly.  
 
